Free Trial

Arvinas (ARVN) Stock Price, News & Analysis

Arvinas logo
$22.69 +1.05 (+4.85%)
(As of 11/20/2024 ET)

About Arvinas Stock (NASDAQ:ARVN)

Key Stats

Today's Range
$21.17
$22.71
50-Day Range
$21.64
$28.04
52-Week Range
$20.28
$53.08
Volume
744,090 shs
Average Volume
718,161 shs
Market Capitalization
$1.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$61.08
Consensus Rating
Moderate Buy

Company Overview

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Arvinas Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
62nd Percentile Overall Score

ARVN MarketRank™: 

Arvinas scored higher than 62% of companies evaluated by MarketBeat, and ranked 612th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Arvinas has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 13 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Arvinas has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Arvinas' stock forecast and price target.
  • Earnings Growth

    Earnings for Arvinas are expected to decrease in the coming year, from ($3.32) to ($4.38) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Arvinas is -4.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Arvinas is -4.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Arvinas has a P/B Ratio of 1.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Arvinas' valuation and earnings.
  • Percentage of Shares Shorted

    12.81% of the outstanding shares of Arvinas have been sold short.
  • Short Interest Ratio / Days to Cover

    Arvinas has a short interest ratio ("days to cover") of 16.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Arvinas has recently decreased by 5.58%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Arvinas does not currently pay a dividend.

  • Dividend Growth

    Arvinas does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.81% of the outstanding shares of Arvinas have been sold short.
  • Short Interest Ratio / Days to Cover

    Arvinas has a short interest ratio ("days to cover") of 16.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Arvinas has recently decreased by 5.58%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Arvinas has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Arvinas this week, compared to 4 articles on an average week.
  • Search Interest

    5 people have searched for ARVN on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Arvinas to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Arvinas insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.23% of the stock of Arvinas is held by insiders.

  • Percentage Held by Institutions

    95.19% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Arvinas' insider trading history.
Receive ARVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

ARVN Stock News Headlines

Arvinas price target lowered to $88 from $90 at BMO Capital
Download Our Tesla Ebook For Free
Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.
Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode
Arvinas initiated with an Overweight at Stephens
Arvinas to Participate in Upcoming Investor Conferences
See More Headlines

ARVN Stock Analysis - Frequently Asked Questions

Arvinas' stock was trading at $41.16 at the start of the year. Since then, ARVN shares have decreased by 44.9% and is now trading at $22.69.
View the best growth stocks for 2024 here
.

Arvinas, Inc. (NASDAQ:ARVN) issued its quarterly earnings data on Wednesday, October, 30th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.88) by $0.20. Arvinas's quarterly revenue was up 196.0% compared to the same quarter last year.

Arvinas (ARVN) raised $100 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

Arvinas' top institutional investors include FMR LLC (4.20%), RTW Investments LP (4.05%), Bellevue Group AG (3.47%) and State Street Corp (2.39%). Insiders that own company stock include John G Houston, Sean A Cassidy, Ian Taylor, Ronald Peck, Briggs Morrison and Liam Ratcliffe.
View institutional ownership trends
.

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arvinas investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

Last Earnings
10/30/2024
Today
11/20/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/25/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ARVN
Fax
N/A
Employees
445
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$61.08
High Stock Price Target
$88.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+169.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.93
Research Coverage
14 Analysts

Profitability

Net Income
$-367,300,000.00
Pretax Margin
-190.01%

Debt

Sales & Book Value

Annual Sales
$78.50 million
Book Value
$11.99 per share

Miscellaneous

Free Float
65,119,000
Market Cap
$1.56 billion
Optionable
Optionable
Beta
1.96
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

This page (NASDAQ:ARVN) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners